8.7 USD
-0.09 (-1.02%)
Overall VALN gets a fundamental rating of 3 out of 10. We evaluated VALN against 530 industry peers in the Biotechnology industry. VALN has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, VALN is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year VALN has reported negative net income.
In the past year VALN has reported a negative cash flow from operations.
In the past 5 years VALN always reported negative net income.
In multiple years VALN reported negative operating cash flow during the last 5 years.
1.2 Ratios
VALN's Return On Assets of -18.09% is fine compared to the rest of the industry. VALN outperforms 77.92% of its industry peers.
Looking at the Return On Equity, with a value of -45.87%, VALN is in the better half of the industry, outperforming 67.92% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -18.09% | ||
| ROE | -45.87% | ||
| ROIC | N/A |
ROA(3y)-15.85%
ROA(5y)-14.17%
ROE(3y)-50.34%
ROE(5y)-55.45%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
VALN has a better Gross Margin (48.94%) than 75.28% of its industry peers.
VALN's Gross Margin has declined in the last couple of years.
VALN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 48.94% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.2%
GM growth 5Y-7.06%
2. Health
2.1 Basic Checks
VALN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, VALN has more shares outstanding
VALN has more shares outstanding than it did 5 years ago.
VALN has a better debt/assets ratio than last year.
2.2 Solvency
VALN has an Altman-Z score of 0.39. This is a bad value and indicates that VALN is not financially healthy and even has some risk of bankruptcy.
VALN has a Altman-Z score of 0.39. This is in the better half of the industry: VALN outperforms 61.32% of its industry peers.
A Debt/Equity ratio of 0.80 indicates that VALN is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.80, VALN is doing worse than 73.96% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.8 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.39 |
ROIC/WACCN/A
WACC7.93%
2.3 Liquidity
VALN has a Current Ratio of 2.27. This indicates that VALN is financially healthy and has no problem in meeting its short term obligations.
VALN has a Current ratio of 2.27. This is in the lower half of the industry: VALN underperforms 73.77% of its industry peers.
VALN has a Quick Ratio of 1.77. This is a normal value and indicates that VALN is financially healthy and should not expect problems in meeting its short term obligations.
VALN has a worse Quick ratio (1.77) than 77.55% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.27 | ||
| Quick Ratio | 1.77 |
3. Growth
3.1 Past
VALN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -1180.00%.
VALN shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 10.32%.
Measured over the past years, VALN shows a small growth in Revenue. The Revenue has been growing by 6.09% on average per year.
EPS 1Y (TTM)-1180%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-271.43%
Revenue 1Y (TTM)10.32%
Revenue growth 3Y-21.31%
Revenue growth 5Y6.09%
Sales Q2Q%-35.76%
3.2 Future
Based on estimates for the next years, VALN will show a very strong growth in Earnings Per Share. The EPS will grow by 55.46% on average per year.
The Revenue is expected to grow by 17.32% on average over the next years. This is quite good.
EPS Next Y-664.71%
EPS Next 2Y-114.88%
EPS Next 3Y109.43%
EPS Next 5Y55.46%
Revenue Next Year-6.69%
Revenue Next 2Y2.34%
Revenue Next 3Y27.3%
Revenue Next 5Y17.32%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
VALN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VALN. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
VALN's earnings are expected to grow with 109.43% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-114.88%
EPS Next 3Y109.43%
5. Dividend
5.1 Amount
VALN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:VALN (12/30/2025, 10:36:01 AM)
8.7
-0.09 (-1.02%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners22.69%
Inst Owner Change16.64%
Ins Owners0.22%
Ins Owner ChangeN/A
Market Cap747.48M
Revenue(TTM)169.58M
Net Income(TTM)-85.51M
Analysts81.82
Price Target15.2 (74.71%)
Short Float %0.2%
Short Ratio6.74
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)59.78%
Min EPS beat(2)56.68%
Max EPS beat(2)62.87%
EPS beat(4)3
Avg EPS beat(4)14.13%
Min EPS beat(4)-115.24%
Max EPS beat(4)62.87%
EPS beat(8)4
Avg EPS beat(8)3.13%
EPS beat(12)6
Avg EPS beat(12)-23.48%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)21.69%
Min Revenue beat(2)16.4%
Max Revenue beat(2)26.97%
Revenue beat(4)3
Avg Revenue beat(4)10.09%
Min Revenue beat(4)-4.78%
Max Revenue beat(4)26.97%
Revenue beat(8)4
Avg Revenue beat(8)1.3%
Revenue beat(12)7
Avg Revenue beat(12)19.63%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-9.46%
PT rev (3m)-10.26%
EPS NQ rev (1m)0%
EPS NQ rev (3m)10.93%
EPS NY rev (1m)-6.3%
EPS NY rev (3m)-11.21%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-8.54%
Revenue NY rev (1m)-3.01%
Revenue NY rev (3m)-9.69%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 2.18 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 3.41 | ||
| P/tB | 3.91 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.4
EYN/A
EPS(NY)-0.71
Fwd EYN/A
FCF(TTM)-0.37
FCFYN/A
OCF(TTM)-0.16
OCFYN/A
SpS3.99
BVpS2.55
TBVpS2.23
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -18.09% | ||
| ROE | -45.87% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 48.94% | ||
| FCFM | N/A |
ROA(3y)-15.85%
ROA(5y)-14.17%
ROE(3y)-50.34%
ROE(5y)-55.45%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.2%
GM growth 5Y-7.06%
F-Score4
Asset Turnover0.62
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.8 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 71.71% | ||
| Cap/Sales | 5.14% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.27 | ||
| Quick Ratio | 1.77 | ||
| Altman-Z | 0.39 |
F-Score4
WACC7.93%
ROIC/WACCN/A
Cap/Depr(3y)101.58%
Cap/Depr(5y)231.17%
Cap/Sales(3y)9.04%
Cap/Sales(5y)14.31%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1180%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-271.43%
EPS Next Y-664.71%
EPS Next 2Y-114.88%
EPS Next 3Y109.43%
EPS Next 5Y55.46%
Revenue 1Y (TTM)10.32%
Revenue growth 3Y-21.31%
Revenue growth 5Y6.09%
Sales Q2Q%-35.76%
Revenue Next Year-6.69%
Revenue Next 2Y2.34%
Revenue Next 3Y27.3%
Revenue Next 5Y17.32%
EBIT growth 1Y-49.96%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-269.56%
EBIT Next 3Y56.42%
EBIT Next 5Y30.38%
FCF growth 1Y88.22%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y94.27%
OCF growth 3YN/A
OCF growth 5YN/A
VALNEVA SE - ADR / VALN FAQ
What is the ChartMill fundamental rating of VALNEVA SE - ADR (VALN) stock?
ChartMill assigns a fundamental rating of 3 / 10 to VALN.
What is the valuation status of VALNEVA SE - ADR (VALN) stock?
ChartMill assigns a valuation rating of 1 / 10 to VALNEVA SE - ADR (VALN). This can be considered as Overvalued.
How profitable is VALNEVA SE - ADR (VALN) stock?
VALNEVA SE - ADR (VALN) has a profitability rating of 2 / 10.
Can you provide the financial health for VALN stock?
The financial health rating of VALNEVA SE - ADR (VALN) is 3 / 10.